Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 20,930 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-treatment Clear all

Conditions: Chronic Heart Failure, Cognitive Impairment
Interventions: Angiotensin-(1-7), Memory Training; Drug · Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 55 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetic Foot Ulcers
Interventions: Granexin gel, Vehicle gel; Drug · Other
Lead sponsor: Xequel Bio, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Doral, Florida • Hialeah, Florida + 3 more

Conditions: Non-Hodgkin Lymphoma
Interventions: Entospletinib, Vincristine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Hattiesburg, Mississippi • Charleston, South Carolina

Conditions: Actinic Keratoses
Interventions: Imiquimod; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Neoplasms
Interventions: Regorafenib (Stivarga, BAY73-4506); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more

Conditions: Anaemia
Interventions: GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Type 1 Diabetes
Interventions: Cognitive Behavioral Therapy, Mindfulness Based Stress Reduction, Diabetes Support and Education; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 16 Years to 20 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cocaine Dependence
Interventions: Contingency Management; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab; Biological
Lead sponsor: Simcha IL-18, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Clostridium Difficile Infection
Interventions: SER-262, Placebo; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Allogeneic Myeloma Vaccine, Prevnar-13; Drug · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Leukemia, Juvenile Myelomonocytic, JMML, JCML, Neurofibromatosis 1, CBL Syndrome
Interventions: Trametinib, Azacitidine, Fludarabine, Cytarabine; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Month to 21 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 18 more

Conditions: Glioblastoma, Recurrent Glioblastoma, GBM
Interventions: Niraparib, Optune, Planned surgical resection; Drug · Device · Procedure
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stroke
Interventions: Telerehabilitation Therapy, In-Clinic Therapy; Device · Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Irvine, California • San Diego, California • Jacksonville, Florida + 9 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Durvalumab (MEDI 4736), Radiotherapy; Drug · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 3
States / cities: Los Angeles, California • Denver, Colorado • New York, New York

Conditions: Low Back Pain, Neck Pain
Interventions: Engagement of clinic leadership (System Intervention - Usual Care), Engagement of clinic leadership (System Intervention - STEPPT), Patient Registry (System Intervention - STEPPT), Delivery of Patient Education Materials (System Intervention - Usual Care), Delivery of Patient Education Materials (System Intervention - STEPPT), Referral Specialist Training (System Intervention - Usual Care), Patient Health Navigator Training (System Intervention - STEPPT), Care Navigation (System Intervention - STEPPT), Care navigation audit and feedback (System Intervention - STEPPT), Primary Care Provider training (Provider Intervention - STEPPT), Nurse/Medical Assistant Training (Provider Intervention - STEPPT), Provider feedback on PT referral and adherence (Provider Intervention - STEPPT), Patient education on spine pain condition (Patient Intervention - Usual Care), Patient education on spine pain condition (Patient Intervention - STEPPT), Patient Education on Physical Referral by Providers (Patient Intervention - Usual Care), Patient Education on Physical Referral by Providers (Patient Intervention - STEPPT), Electronic Patient Education on Physical Therapy Referral (Patient Intervention - STEPPT), Patient education on physical therapy referral by Referral Specialist (Patient Intervention - Usual Care), Patient education on physical therapy referral by Patient Health Navigator (Patient Intervention - STEPPT), Care Navigation (System Intervention - Usual Care), Monitoring of PT referral and adherence rates (System Intervention - STEPPT), Monitoring of PT referral and adherence rates (System intervention - Usual Care); Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years and older
Enrollment: 17,587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Diego, California

Conditions: Leukemia, Lymphoma
Interventions: Pegfilgrastim, Rituximab, Cyclophosphamide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 70 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autism
Interventions: Placebo, Docosahexanoic Acid; Dietary Supplement
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 5 Years to 17 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Nasal Congestion and Inflammations
Interventions: Sonu; Device
Lead sponsor: Third Wave Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: End-Stage Renal Disease
Interventions: Anakinra, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Non Small Cell Lung
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Blood Oxygen Level Dependent Imaging, Papaverine Hydrochloride, Stereotactic Body Radiation Therapy; Procedure · Drug · Radiation
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Lung Cancer
Interventions: Carboplatin, Proton Radiotherapy, Paclitaxel; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Epidermolysis Bullosa
Interventions: SD-101 dermal cream (6%); Drug
Lead sponsor: Scioderm, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 7
States / cities: Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more

Search by objective public record fields.

Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients

A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Comparing Immune Responses to Topical Imiquimod

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers

Reducing Stress in Adolescents and Young Adults With Type 1 Diabetes to Improve Diabetes Care

Treating Cocaine Abuse: A Behavioral Approach

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Niraparib/TTFields in GBM

Telerehabilitation in the Home Versus Therapy In-Clinic for Patients With Stroke

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

Stratified Targeted Engagement From Primary Care to Physical Therapy (STEPPT)

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial

Sonu Nasal Congestion Relief Study in Patients Suffering From Moderate to Severe Nasal Congestion

Anti-Cytokine Therapy for Hemodialysis InflammatION

Clinical Impact of EUS in Staging NSCLC

Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa